The FDA has approved Wyeth Pharmaceuticals' antibiotic Tygacil to treat bacterial infections. The move gives hospitals another weapon in the war against new and disturbingly durable infections, including methicillin-resistant staph aureus, or MRSA, which has spread beyond hospitals and into the community. The new antibiotic is intended to combat a broad range of bacteria. Side effects include nausea and vomiting.
- read this article from the AP for more